RNAC – cartesian therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Cartesian Therapeutics Announces New Employment Inducement Grants
GSK (GSK) Tops Q4 Earnings and Revenue Estimates [Yahoo! Finance]
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $41.00 price target on the stock.
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
Form SCHEDULE 13G/A Cartesian Therapeutics, Filed by: FMR LLC
Form 8-K Cartesian Therapeutics, For: Jan 27
Form SCHEDULE 13D/A Cartesian Therapeutics, Filed by: SPRINGER TIMOTHY A
Form 4 Cartesian Therapeutics, For: Jan 13 Filed by: SPRINGER TIMOTHY A
Form EFFECT Cartesian Therapeutics,
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.